Epinephrine (L-adrenaline) is a bulk active pharmaceutical ingredient used to manufacture or compound prescription products.
Spectrum Laboratory Products is voluntarily recalling three lots of epinephrine (L-adrenaline), a bulk active pharmaceutical ingredient (API) used to manufacture or compound prescription products. Customer complaints have found the product to be discolored.
Epinephrine (L-adrenaline) bulk API powder is used in manufacturing and compounding of epinephrine prescription products, which are used to treat patients with anaphylaxis and other severe immediate hypersensitivity reactions. The use of a finished dose product manufactured or compounded with this recalled product could result in less-effective product.
Spectrum Laboratory Products has not received any reports of adverse events related to this recall.
Epinephrine (L-adrenaline) is packaged in amber glass bottles enclosed in a vacuum sealed pouch. It can be identified by the Spectrum catalog number EP130, and it was distributed directly from facilities nationwide in the United States and to Canada.
The affected lots include:
NDC numbers of the impacted products and package size can be found here.
ICER Identifies 5 Drugs with Unsupported Price Increases
December 12th 2024The Institute for Clinical and Economic Review has identified five drugs — Biktarvy, Darzalex, Entresto, Cabometyx, and Xeljanz — with prices increases that are not supported by new clinical evidence, with a total of $815 million in added costs to U.S. payers in 2023.
Read More
FDA Sets Goal Date for Lymphoma Drug Columvi
December 5th 2024The combination of Columvi, gemcitabine and oxaliplatin is the first CD20xCD3 bispecific antibody to show positive results in a randomized diffuse large B-cell lymphoma phase 3 trial. The FDA’s decision is expected by July 20, 2025.
Read More